How big is DURECT Corp.?

As of Jun 18, DURECT Corp. has a market capitalization of 19.73 million, with net sales of 4.87 million and a net profit of -13.87 million over the latest four quarters. Shareholder's funds are 9.13 million, and total assets are valued at 18.35 million.

As of Jun 18, DURECT Corp. has a market capitalization of 19.73 million, classifying it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 4.87 million, while the sum of net profit for the same period is -13.87 million.<BR><BR>As of Dec 24, the shareholder's funds amount to 9.13 million, and the total assets are valued at 18.35 million.

What does DURECT Corp. do?

Durect Corporation is a biopharmaceutical company focused on developing treatments for metabolic disorders and acute organ injuries. As of March 2025, it reported net sales of $0 million and a net loss of $4 million, with a market cap of $19.73 million.

Overview:<BR>Durect Corporation is a biopharmaceutical company engaged in research and development programs within the Pharmaceuticals & Biotechnology industry, focusing on various product candidates for metabolic disorders, acute organ injuries, and laboratory research.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 19.73 Million (Micro Cap) <BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.34 <BR>Return on Equity: -282.90% <BR>Price to Book: 3.69 <BR><BR>Contact Details:<BR>Address: 10260 Bubb Rd, CUPERTINO CA: 95014-4166 <BR>Tel: ['1 408 7771417', '1 408 3461052'] <BR>Fax: 1 408 7773577 <BR>Website: http://www.durect.com

Should I buy, sell or hold DURECT Corp.?

Who are in the management team of DURECT Corp.?

As of March 2022, the management team of DURECT Corp. includes David Hoffmann (Independent Chairman), James Brown (President and CEO), and Directors Mohammad Azab, Gail Maderis, Simon Benito, Terrence Blaschke, and Gail Farfel. They oversee the company's strategic direction and operations.

As of March 2022, the management team of DURECT Corp. includes the following individuals:<BR><BR>- Mr. David Hoffmann, who serves as the Independent Chairman of the Board.<BR>- Mr. James Brown, who is the President, Chief Executive Officer, and Director.<BR>- Dr. Mohammad Azab, who is a Director.<BR>- Ms. Gail Maderis, who is also a Director.<BR>- Mr. Simon Benito, who serves as an Independent Director.<BR>- Dr. Terrence Blaschke, who is an Independent Director.<BR>- Dr. Gail Farfel, who is another Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Is DURECT Corp. technically bullish or bearish?

As of September 10, 2025, DURECT Corp. shows a mildly bullish trend with a strong year-to-date return of 154.67%, despite mixed signals from technical indicators and underperformance over the longer term.

As of 10 September 2025, the technical trend for DURECT Corp. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by a bullish MACD on the weekly and a bullish daily moving average. However, the weekly and monthly RSI readings are bearish, indicating some weakness. The Bollinger Bands and KST are both mildly bullish on both weekly and monthly time frames, while the Dow Theory shows a mixed signal with mildly bullish weekly and mildly bearish monthly indicators. <BR><BR>In terms of performance, DURECT Corp. has significantly outperformed the S&P 500 year-to-date with a return of 154.67% compared to the S&P 500's 12.22%, but it has underperformed over longer periods, particularly in the 3-year and 5-year returns.